---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-317541"
form_type: "8-K"
ticker: "IDYA"
cik: "0001676725"
company_name: "IDEAYA Biosciences, Inc."
filed_at: "2025-12-12T23:59:59+00:00"
generated_at: "2026-05-16T13:21:51.333821+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GSK terminates collaboration on IDE275 and IDE705; programs returning to IDEAYA

## Summary
- GSK gave written notice on Dec 9, 2025 to terminate the June 2020 Collaboration, Option and License Agreement.
- Termination effective March 9, 2026; 90-day transition for GSK to transfer Werner Helicase (IDE275) and Pol Theta (IDE705) programs.
- IDEAYA will evaluate strategic options for IDE275 and IDE705 in 2026.
- Cash runway guidance into 2030 remains unchanged despite the termination.

## SEC filing metadata
- accession: 0001193125-25-317541
- form_type: 8-K
- ticker: IDYA
- cik: 0001676725
- company_name: IDEAYA Biosciences, Inc.
- filed_at: 2025-12-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/0001193125-25-317541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1676725/000119312525317541/d800445d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-317541
- JSON: https://secwatch.observer/filing/0001193125-25-317541.json
- Plain text: https://secwatch.observer/filing/0001193125-25-317541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.